PHASE III PROGRESS
October 7th, 2019, Citius Completes 40% – Triggers Data Being Analyzed (is it working?).
December 19th, 2019 – Data Analysis Back, Results Positive.
February 4th, 2020 – Citius Completes 50%.
Spring/Summer 2020, Citius Scheduled to Complete 75% – Triggering Data Being Analyzed (is it superior?).
“As a reminder, the current Phase III trial being conducted compares the Citius Mino-Lok therapy (MLT) to the standard of care (aka the competition), which is antibiotic lock therapy (ALT). Being superior could result in the catheter remaining in the patient as opposed to having to be removed and replaced – a very scary procedure. Each year, up to approximately 500,000 central venous catheters of the 7 million used in the U.S. become infected.” Biotech Stock Review
“CVCs are a lifeline for many critically ill or chronically ill patients. However, CVCs are frequently associated with bloodstream infections (CRBSIs) which are the leading cause of healthcare-associated infections (HAIs) in the United States with substantial patient morbidity and mortality. The current standard of care is treating the bacteremia with culture-directed systemic antibiotic therapy with the removal of the infected CVC and replacement with a new CVC at a different site. With cancer and hemodialysis patients, this may be difficult or impossible because of the unavailability of a suitable vascular site.”
“Also, there is a high degree of relapse and poor response to therapy when replacing CVCs. Mino-Lok therapy has the potential to be significantly safer than replacing a CVC. Many bacteremic patients have underlying coagulopathy making replacement risky. There are also mechanical complications (misplacement, arterial puncture, hemopneumothorax, etc.) associated with CVC removal and reinsertion; and, there is significant patient discomfort in the CVC replacement procedure.”
Dr. Issam Raad, who is considered one of the leading experts in the world in the field of vascular catheter and healthcare-related infections.
Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial.
Next major milestone in Mino-Lok trial is the 75% interim analysis for superior efficacy and is expected in first half of 2020.
CRANFORD, N.J., Feb. 4, 2020 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical-care drug products, today announced that the Company’s lead program, Mino-Lok vs. standard-of-care (“SOC”) antibiotic locks, has randomized its 72nd patient, thereby passing the halfway point for enrollment in this Phase 3 trial. The Company previously announced the results of a futility analysis when it passed the threshold of 40% of patients completing end of therapy. That analysis showed a positive outcome, as it met the prespecified interim futility analysis criteria. The next major milestone in the Mino-Lok trial, expected to be achieved in the first half of 2020, will be the 75% interim analysis for superior efficacy. The endpoints for this analysis require that the time to catheter failure be at least 38 days for Mino-Lok vs. 21 days for SOC antibiotic locks.
“We are extremely happy that our trial is proceeding according to plan. The independent drug monitoring committee (“DMC”) will next evaluate the clinical data at the 75% level of enrollment to see if Mino-Lok demonstrates superior efficacy versus SOC antibiotic locks,” said Myron Holubiak, Chief Executive Officer of Citius. “We believe that the Mino-Lok clinical trial will be a major contribution to the study of catheter-related bloodstream infections (CRBSI) and the utility of antibiotic locks. Effective alternatives are needed to the practice of removing and replacing infected central venous lines.”
About Mino-Lok®
Each year, up to approximately 500,000 central venous catheters of the 7 million used in the U.S. become infected and lead to CRBSIs, increasing both patient morbidity risk and costs to the medical system. It has been shown that antibiotics alone are unable to penetrate the biofilm caused by bacteria, and there are currently no approved therapies for salvaging infected central venous catheters. Mino-Lok is an antibiotic lock solution that is being developed to treat patients with CRBSIs in combination with an appropriate systemic antibiotic(s) to preserve central venous access and to avoid the complications and morbidities associated with catheter removal and reinsertion. Mino-Lok penetrates biofilm, eradicates bacteria and salvages infected, indwelling vascular catheters while providing anticlotting properties. Mino-Lok has the potential to change the standard of care for the management of these serious infections. The market potential for an effective antibiotic lock therapy is estimated to be $750+ million per year in the U.S. and approximately $1.5 billion worldwide.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical-care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages over existing therapeutic approaches. For more information, please visit www.citiuspharma.com.
Safe Harbor
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “should,” and “may,” along with other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from those currently anticipated are risks associated with conducting our Phase III trial for Mino-Lok, including our ability to complete patient enrollment; risks relating to our need for substantial additional funds; possible changes in the estimated markets for our product candidates and the acceptance thereof by any market; risks relating to the results of research and development activities; risks associated with developing Mino-Wrap, including the risk that preclinical results may not be predictive of clinical results or of our ability to file an IND; uncertainties relating to preclinical and clinical testing; uncertainties associated with the early stage of products under development; risks related to our growth strategy; risks related to our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; uncertainties relating to our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; uncertainties relating to our ability to attract, integrate and retain key personnel; possible changes in government regulation; risks associated with patent and intellectual property matters; and risks relating to competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Andrew Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
(M) 646-522-8410
[email protected]
